Senhwa Biosciences (ROCO:6492) Tax Expense: NT$1.33 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6492 Senhwa Biosciences Inc ROCO:6492
70 GF Score
Price NT$43.70
GF Value NT$46.74
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Senhwa Biosciences Tax Expense?

Senhwa Biosciences ROCO:6492 -1.35% 70 Tax Expense is NT$1.33 Mil as of Dec. 2025. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review.

Senhwa Biosciences's tax expense for the months ended in Dec. 2025 was NT$1.34 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.33 Mil.


Senhwa Biosciences  (ROCO:6492) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Senhwa Biosciences Tax Expense Related Terms


Senhwa Biosciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Senhwa Biosciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senhwa Biosciences Tax Expense Chart

Senhwa Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 1.37 1.26 1.28 1.33

Senhwa Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 -0.00 0.00 0.00 1.34
ROCO:6492
70GF Score
Senhwa Biosciences Inc ROCO:6492
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senhwa Biosciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of NT$1.33 Mil mean?
Senhwa Biosciences (ROCO:6492) has a Tax Expense of NT$1.33 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Senhwa Biosciences and its competitors.
Is Senhwa Biosciences' Tax Expense too high?
Senhwa Biosciences' current Tax Expense is NT$1.33 Mil. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' Tax Expense compare to VRTX and REGN?
Senhwa Biosciences' Tax Expense of NT$1.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Senhwa Biosciences and its competitors. Senhwa Biosciences's current Tax Expense is NT$1.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current Tax Expense is NT$1.33 Mil. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current Tax Expense is NT$1.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?

Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued. The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74. GuruFocus considers Senhwa Biosciences to be Fairly Valued.

Key valuation signals for ROCO:6492:

  • Tax Expense: NT$1.33 Mil
  • GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Senhwa Biosciences Business Description

Address Peihsin Road, 10th Floor, No. 225, Section 3, Hsintien District, New Taipei City, TWN, 23143
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score

Get the complete analysis for ROCO:6492

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.70
Price
NT$46.74
GF Value